/주식/AUPH
AUPH

AUPH

USD

Aurinia Pharmaceuticals Inc Ordinary Shares

$8.210+0.000 (0.000%)

실시간 가격

Healthcare
생명공학
캐나다

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$8.210

고가

$8.380

저가

$8.200

거래량

0.11M

기업 기본 정보

시가총액

1.1B

산업

생명공학

국가

Canada

거래 통계

평균 거래량

1.40M

거래소

NGM

통화

USD

52주 범위

저가 $4.99현재가 $8.210고가 $10.67

AI 분석 리포트

마지막 업데이트: 2025년 5월 2일
AI 생성데이터 소스: Yahoo Finance, Bloomberg, SEC

AUPH (Aurinia Pharmaceuticals Inc Ordinary Shares): What's Happening and What to Watch

Stock Symbol: AUPH Generate Date: 2025-05-02 13:53:32

Alright, let's break down what's been going on with Aurinia Pharmaceuticals (AUPH) based on the latest info. Think of this as chatting about the stock with a friend who wants the lowdown without all the confusing finance talk.

Recent News Buzz: What's the Vibe?

The main piece of news hitting the wires recently is that a big, influential group called Institutional Shareholder Services (ISS) is telling Aurinia shareholders to vote "FOR" all the company's proposals at the upcoming annual meeting.

What does this mean simply? ISS is like a major advisor for large investors deciding how to vote on company matters. When they recommend voting for management's plans, it generally signals that they see the company's direction and proposals as reasonable or beneficial. So, this news feels pretty positive and supportive for Aurinia's current leadership and strategy. It's not earth-shattering, but it's a good sign that a key advisor is on board.

Price Check: Where Has the Stock Been Heading?

Looking at the stock's movement over the last month or two, it's been a bit of a ride. We saw a noticeable dip around late February, dropping from the high $7s down towards the mid-$6s on some heavy volume. That kind of sharp drop often gets people's attention.

Since that dip, though, the stock has mostly recovered and has been trading in a range, often hovering around the $8 mark. Lately, in late April and early May, it's been bouncing between roughly $7.90 and $8.30. The last recorded price point shows it trading around $8.31.

Now, what about the AI's crystal ball? The prediction model suggests the price might stay flat today (0.00% change), but then sees a slight upward nudge over the next couple of days (+0.85% tomorrow, +2.85% the day after). So, the AI thinks the recent stability might lean slightly positive in the very near term.

Putting It Together: Outlook & Some Ideas

So, we've got supportive news from a key advisor, a stock price that recovered from a recent dip and is now trading in a relatively stable range, and an AI prediction pointing to a small potential upward move soon.

Based on just this picture, the situation seems to lean towards a 'hold' for those already in, or perhaps considering 'accumulating' shares, maybe on any small dips. The positive news and the AI's forecast suggest things aren't looking immediately negative.

If you were thinking about potentially getting in, the current price area, around $8.31, looks like it's within the recent trading range. The AI's recommendation data even flagged potential entry points around $8.25 to $8.28, which are very close to where it's been trading. So, the current levels or a slight pullback could be areas to watch, aligning with recent price action and the AI's view.

What about managing risk or thinking about where to take profits? The AI data offers some potential levels here too. It suggests a stop-loss around $7.39. Looking at the historical data, that's below the recent trading range and significantly below the recovery point after the late Feb dip, which makes sense as a level to consider if the stock starts heading south again. For taking profits, the AI suggests $8.37. That's just a hair above the current price and aligns with the AI's short-term upward prediction. It's a near-term target to keep in mind.

Company Context Snapshot

Just to remember what Aurinia does – it's a biotech company focused on treating autoimmune diseases, specifically with its main drug LUPKYNIS for lupus nephritis. The ISS recommendation is about the overall company governance and direction, which is important for any company, but especially for a biotech where future plans and management stability are key. Also, keep in mind the company's valuation metrics, like the P/E ratio (around 15.4 based on Yahoo data, though other calculations show it much higher), suggest it's not a 'cheap' stock based on current earnings, which is common in biotech but something to be aware of.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research or consult with a qualified financial advisor before making any investment decisions.

관련 뉴스

BusinessWire

ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ:AUPH) today announced that leading independent proxy advisor Institutional Shareholder Services ("ISS") has recommended that Aurinia shareholders vote

더 보기
ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

AI 예측Beta

AI 추천

강세

업데이트 시간: 2025년 5월 4일 오전 11:03

약세중립강세

61.7% 신뢰도

리스크 & 트레이딩

리스크 수준3/5
중위험
적합 대상
성장
트레이딩 가이드

진입점

$8.25

익절

$8.37

손절

$7.38

핵심 요소

DMI는 약세 추세(ADX:12.8, +DI:4.1, -DI:7.8)를 보여 주의를 요합니다.
현재 가격이 지지선($8.24)에 매우 근접하여 강력한 매수 기회를 시사합니다.
거래량은 평균(13,985)의 5.5배로 극도로 강력한 매수 압력을 나타냅니다.
MACD -0.0105이(가) 신호선 -0.0052 아래에 있어 약세 교차를 나타냅니다.

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기